Integrating scRNA-seq and bulk RNA-seq to characterize infiltrating cells in the colorectal cancer tumor microenvironment and construct molecular risk models

Qi Wang; Yi-Fan Zhang; Chen-Long Li; Yang Wang; Li Wu; Xing-Ru Wang; Tai Huang; Ge-Liang Liu; Xing Chen; Qi Yu; Pei-Feng He

doi:doi:10.18632/aging.205263

← Back

Research Paper Volume 15, Issue 23 pp 13799—13821

Integrating scRNA-seq and bulk RNA-seq to characterize infiltrating cells in the colorectal cancer tumor microenvironment and construct molecular risk models

Figure 9. Evaluation of drug sensitivity. The comparisons in IC50 value between low-risk and high-risk groups. The ordinate shows the IC50 value of anticancer drug target sensitivity. Lower IC50 values are associated with higher sensitivity to the anticancer drug. (A) Bexaroten. (B) Dasatinib. (C) Elesclomol. (D) Gefitinib. (E) Lenalidomide. (F) Nilotinib. (G) Parthenolide. (H) Pazopanib. (I) Rapamycin. (J) Shikonin. (K) Sunitinib. (L) Temsirolimus. (M) Vinblastine. (N) Vorinostat.